EBITDA: Income before interest, taxes, depreciation and amortization.
Cullinan Therapeutics, Inc. (CGEM) had EBITDA of $-55.18M for the most recently reported fiscal quarter, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-50.71M |
|
-- |
|
-- |
|
$55.26M |
|
$-55.26M |
|
$4.55M |
|
$-50.71M |
|
$-50.71M |
|
$-50.71M |
|
$-50.71M |
|
$-50.71M |
|
$-50.71M |
|
$-55.26M |
|
|
EBITDA |
$-55.18M |
59.05M |
|
59.05M |
|
$-0.78 |
|
$-0.78 |
|
| Balance Sheet Financials | |
$386.76M |
|
$0.42M |
|
$61.62M |
|
$448.37M |
|
$37.74M |
|
-- |
|
$1.90M |
|
$39.64M |
|
$408.73M |
|
$408.73M |
|
$408.73M |
|
60.24M |
|
| Cash Flow Statement Financials | |
$-175.75M |
|
$179.99M |
|
$1.09M |
|
$83.00M |
|
$88.33M |
|
$5.33M |
|
$36.04M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
10.25 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-175.80M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-12.41% |
|
-12.41% |
|
-11.31% |
|
-12.41% |
|
$6.78 |
|
$-2.98 |
|
$-2.98 |
|